Pliant Therapeutics Inc
(NAS:PLRX)
$
10.71
-0.49 (-4.38%)
Market Cap: 646.09 Mil
Enterprise Value: 218.36 Mil
PE Ratio: 0
PB Ratio: 1.48
GF Score: 34/100 - Pliant Therapeutics Inc INTEGRIS-PSC Phase 2a Trial Results Call TranscriptFeb 05, 2024
- Pliant Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 09, 2024
- Pliant Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 28, 2023
- Pliant Therapeutics Inc INTEGRIS-PSC Interim Phase 2a Data Presentation TranscriptSep 26, 2023
- Pliant Therapeutics Inc at Canaccord Genuity Growth Conference TranscriptAug 10, 2023
- Pliant Therapeutics Inc at RBC Capital Markets Global Healthcare Conference TranscriptMay 17, 2023
- Pliant Therapeutics Inc INTEGRIS-IPF Call TranscriptMay 01, 2023
- Pliant Therapeutics Inc at Needham Healthcare Conference (Virtual) TranscriptApr 19, 2023
- Pliant Therapeutics Inc at Oppenheimer Healthcare Conference (Virtual) TranscriptMar 13, 2023
- Pliant Therapeutics Inc at Cowen Health Care Conference TranscriptMar 08, 2023
- Pliant Therapeutics Inc at SVB Securities Global Biopharma Conference (Virtual) TranscriptFeb 15, 2023
- Pliant Therapeutics Inc Review Data from the 320 mg Group of the INTEGRIS-IPF Phase 2a Trial of Bexotegrast (PLN-74809) in Patients with IPF Call TranscriptJan 23, 2023
- Pliant Therapeutics Inc at Piper Sandler Healthcare Conference TranscriptNov 30, 2022
- Pliant Therapeutics Inc at Evercore ISI HealthCONx Conference (Virtual) TranscriptNov 29, 2022
- Pliant Therapeutics Inc at RBC Capital Markets Biotech Expert Insights: Pulmonary/Lung Disease Mini-Symposium (Virtual) TranscriptOct 07, 2022
- Pliant Therapeutics Inc to Discuss Results from INTEGRIS-IPF Call TranscriptJul 11, 2022
- Pliant Therapeutics Inc Annual Shareholders Meeting TranscriptJun 16, 2022
- Pliant Therapeutics Inc at RBC Capital Markets Global Healthcare Conference TranscriptMay 18, 2022
- Pliant Therapeutics Inc at Needham Healthcare Conference (Virtual) TranscriptApr 12, 2022
Pliant Therapeutics Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 13, 2023 / 06:40PM GMT
Release Date Price:
$28.2
(+0.79%)
Jeff Jones
Oppenheimer & Co. Inc. - Analyst
Good afternoon, everyone, and welcome to the Pliant Therapeutics fireside chat here at the Oppenheimer healthcare conference. I'm Jeff Jones. I'm a senior analyst here on the biotechnology team, and I'm thrilled to welcome the CEO, Bernard Coulie; and the Chief Medical Officer, Ãric Lefebvre.
Welcome, gentlemen. Thank you very much for taking the time to join us this afternoon.
Bernard Coulie
Pliant Therapeutics, Inc. - President & CEO
Thanks, Jeff.
Questions & Answers
Jeff Jones
Oppenheimer & Co. Inc. - Analyst
I guess, to start off, I start off with, for those who aren't familiar with the story, can you give us a quick overview of the company and in particular, your integrin-targeting technology platform?
Bernard Coulie
Pliant Therapeutics, Inc. - President & CEO
Absolutely. So at Pliant, we have been really focused for the past, I would say, six years on developing novel treatments for
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)